Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance following inhaled or intratumoral delivery to solid tumors.
Related Questions
What is the anticipated timeline and regulatory pathway for the inhaled KB707 Phase 2/3 trials in NSCLC, and how might that affect near‑term valuation?
How does the inhaled KB707 platform compare to existing IL‑2/IL‑12 immunotherapies and other NSCLC treatments in terms of efficacy, safety, and market potential?
Will the updated development plan require additional financing, and what are the potential dilution or partnership implications for shareholders?